首页> 外文期刊>Clinical drug investigation >Diclofenac epolamine plus heparin plaster versus diclofenac epolamine plaster in mild to moderate ankle sprain: a randomized, double-blind, parallel-group, placebo-controlled, multicentre, phase III trial.
【24h】

Diclofenac epolamine plus heparin plaster versus diclofenac epolamine plaster in mild to moderate ankle sprain: a randomized, double-blind, parallel-group, placebo-controlled, multicentre, phase III trial.

机译:双氯芬酸依泊拉明加肝素膏与双氯芬酸依泊拉明膏在轻度至中度踝扭伤中的疗效:一项随机,双盲,平行组,安慰剂对照,多中心,III期试验。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: In general sports, ankle sprain is the most frequently reported ankle injury and can cause chronic lateral ankle pain and tenderness. Treatment with NSAIDs is preferred, and several topical NSAID formulations are now available, helping to avoid the systemic adverse events typically associated with oral preparations. OBJECTIVE: To compare the efficacy and tolerability of a newly developed fixed-dose diclofenac epolamine (diclofenac hydroxyethylpyrrolidine, DHEP)/heparin plaster (Flectoparin(R) Tissugel) with that of a DHEP (Flector EP Tissugel(R)) or placebo plaster in the treatment of mild to moderate ankle sprain in adults. METHODS: This was a randomized, double-blind, parallel-group, placebo-controlled, multicentre, phase III study conducted in the emergency medical centres of hospitals or private clinics in Europe. Outpatients aged 18-65 years who had suffered an acute ankle sprain (O'Donoghue grade I or II in severity, with external lateral ligament involvement) within the previous 48 hours and had peri-malleolar oedema were eligible for inclusion. A total of 430 patients were randomized to receive a DHEP/heparin 1.3%/5600 IU (n = 142), DHEP 1.3% (n = 146) or placebo (n = 142) plaster, applied once daily to the injured ankle for a total of 7 days. The primary endpoint was the mean change from baseline in pain on movement on day 3, as measured by a visual analogue scale (VAS). RESULTS: The DHEP/heparin plaster was associated with a significantly (p = 0.002) greater mean reduction from baseline in pain on movement after 3 days of treatment than the DHEP plaster (-24.2 vs -18.8 mm VAS), with each active treatment providing significantly (p
机译:背景:在一般运动中,踝关节扭伤是最常报告的踝关节损伤,可引起慢性侧踝疼痛和压痛。首选使用非甾体抗炎药治疗,现在可以使用几种局部用非甾体抗炎药,从而有助于避免通常与口服制剂相关的全身性不良事件。目的:比较新开发的固定剂量双氯芬酸依泊敏(​​双氯芬酸羟乙基吡咯烷,DHEP)/肝素膏药(Flectoparin®Tissugel)与DHEP(Flector EPTissugel®)或安慰剂膏药的疗效和耐受性成人轻度至中度踝扭伤的治疗。方法:这是在欧洲医院或私人诊所的紧急医疗中心进行的随机,双盲,平行组,安慰剂对照,多中心,III期研究。年龄在18-65岁之间且在过去48小时内患有急性踝关节扭伤(严重程度为O'Donoghue等级I或II,外部外侧韧带受累)且患有睫状周水肿的门诊患者。总共430名患者被随机分配接受DHEP /肝素1.3%/ 5600 IU(n = 142),DHEP 1.3%(n = 146)或安慰剂(n = 142)膏药,每天一次在受伤的脚踝上使用总共7天。主要终点是第3天运动时疼痛相对于基线的平均变化,通过视觉模拟量表(VAS)进行测量。结果:DHEP /肝素石膏治疗3天后的运动疼痛平均基线较DHEP石膏(-24.2 vs -18.8 mm VAS)有显着(p = 0.002)的平均降低,每项积极的治疗均提供比安慰剂(-13.7毫米VAS)明显(p≤0.005)更大的疼痛缓解。 DHEP /肝素和DHEP均可有效缓解其他疼痛,DHEP /肝素接受者在倚靠受伤的肢体上时每天遭受的痛苦明显少于DHEP接受者(p <0.001)。此外,与安慰剂相比,DHEP /肝素对水肿的减轻作用明显更大(仅第7天; p = 0.012)。 DHEP /肝素膏药和DHEP膏药均具有良好的耐受性,不良事件特征与安慰剂相似。局部不良事件很少见,严重程度一般较轻,没有全身性不良反应。结论:固定剂量的DHEP /肝素膏药比DHEP膏药有效,并且在缓解成人轻度至中度急性踝扭伤伴水肿方面具有缓解疼痛甚至可能消肿的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号